Mayo Clinic leads fragmented primary ovarian insufficiency market

By AI, Created 4:28 PM UTC, May 18, 2026, /AGP/ – A new market report says the global primary ovarian insufficiency market is moderately fragmented, with Mayo Clinic leading 2024 sales and the top 10 players holding 21% of revenue. The findings point to growing competition around diagnostics, fertility preservation, biomarker tools and precision reproductive care through 2035.

Why it matters: - The primary ovarian insufficiency market is still open enough for new entrants and partnerships, but clinical complexity and regulatory demands make scale hard to build quickly. - Demand is shifting toward earlier diagnosis, personalized treatment and precision medicine tools that could change how patients are evaluated and managed. - Competitive gains now depend on both care delivery and data-driven diagnostics, not just fertility services alone.

What happened: - The Business Research Company published a 2026 report on the primary ovarian insufficiency market, covering market size, trends and a global forecast for 2026-2035. - Mayo Clinic led global sales in 2024 with a 4% market share. - Johns Hopkins Medicine also held a 4% share in 2024, followed by Cleveland Clinic at 3%. - Royan Institute and Progyny Inc. each held 2% of the market in 2024. - Baptist Health held 2%, while Pristyn Care, CCRM Fertility, Kindbody and Shady Grove Fertility each held 1%.

The details: - The top 10 players accounted for 21% of total market revenue in 2024. - The market is described as moderately fragmented. - Leading companies are competing through diagnostic evaluation services, hormone replacement therapy protocols, fertility preservation consultations and personalized treatment planning. - The report says competitive barriers include strict clinical approval requirements, complex treatment protocols, long-term patient management evidence and the need for reliable diagnostic and therapeutic outcomes. - Major companies named in the market include Mayo Clinic, Johns Hopkins Medicine, Cleveland Clinic, Royan Institute, Progyny Inc., Baptist Health, Pristyn Care, CCRM Fertility, Kindbody, Shady Grove Fertility, Indira IVF Hospital Private Limited, PreventionGenetics LLC, TFP Fertility, Sparsh Diagnostics Pvt. Ltd., Bioscience Institute S.p.A., TCM Healthcare (UK) Ltd., Welling Homeopathy Clinics Pvt. Ltd., IVIRMA Global, The Kingsley Natural Health Clinic and Bristol Menopause. - Major raw material suppliers listed include F. Hoffmann-La Roche Ltd., Merck KGaA, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, bioMérieux SA, Agilent Technologies Inc., QIAGEN N.V., Illumina Inc., Revvity Inc., Waters Corporation, GE HealthCare Technologies Inc., Becton Dickinson and Company, Sysmex Corporation, Hologic Inc., Lonza Group AG, Charles River Laboratories International Inc., Eurofins Scientific SE, Amgen Inc., Exact Sciences Corporation and Guardant Health Inc. - Major wholesalers and distributors include McKesson Corporation, Cardinal Health Inc., AmerisourceBergen Corporation, Medline Industries LP, Owens & Minor Inc., Henry Schein Inc., Patterson Companies Inc., Covetrus Inc., Fisher Scientific International Inc., VWR International LLC and Midland Scientific Inc. - Major end users include Apollo Hospitals Enterprise Limited, Fortis Healthcare Limited, Medanta – The Medicity, Singapore General Hospital, National University Hospital Singapore, Mount Sinai Health System, Kaiser Permanente, Boston IVF, Shady Grove Fertility, IVI-RMA Global, Monash IVF Group, Newcastle Fertility Centre and Karolinska University Hospital. - The report points to advanced assisted reproductive and clinical monitoring platforms as a major competitive trend. - In January 2026, ClinicalTrials.gov recorded study NCT07376460 on proteomic and biological changes after ovarian reactivation treatment in POI patients. - The study is intended to identify molecular protein signatures linked to ovarian recovery and support biomarker discovery, precision diagnostics and therapeutic monitoring. - The report says companies are advancing primary ovarian insufficiency research, building biomarker and genetic platforms, expanding reproductive health infrastructure and integrating AI-driven analytics. - The report also says the market should see more strategic collaborations, product innovation and regional expansion as demand grows.

Between the lines: - The market looks less like a single drug race and more like a multi-layered contest across clinics, diagnostics and fertility infrastructure. - The presence of major hospital systems, fertility networks and diagnostics firms suggests that winning may depend on integrated care pathways rather than one product category. - The study activity around ovarian reactivation shows the field is still evolving scientifically, which could reward companies with stronger research and data capabilities.

What’s next: - The competitive field is likely to keep shifting as biomarker-based diagnostics and AI-supported analytics become more central to care. - Regional expansion and partnerships may matter more as companies try to convert research advances into clinical adoption. - The report’s 2026-2035 forecast signals continued attention on fertility preservation, hormone management and precision reproductive care.

The bottom line: - Mayo Clinic leads a market that remains fragmented, research-heavy and open to companies that can combine clinical care, diagnostics and data tools.